2020, Number 3
<< Back Next >>
Rev Latin Infect Pediatr 2020; 33 (3)
Safety of pentavalent vaccine against rotavirus in Mexico during 2011-2017: surveillance reports
Santibañez-Copado AM, Gómez-Altamirano CM, Romero-Feregrino R, Romero-Cabello R
Language: English
References: 25
Page: 131-137
PDF size: 216.00 Kb.
ABSTRACT
Diarrhoeal rotavirus diseases among children under one year old represent one of the main causes of medical care. Rotavirus vaccines have demonstrated impact on reducing diarrhoea morbidity and mortality worldwide. Thus, the World Health Organization (WHO) recommends to be considered within national immunization programs. In Mexico, the pentavalent rotavirus vaccine is currently used in children under 8 months of age. As part of the surveillance program, monitoring adverse events has improved in the last years, specially focused on the identification of intestinal invagination. The objective of the study was to identify and determine the causality of adverse events given by the pentavalent rotavirus vaccine considering the notifications made in the national system. An observational, descriptive and retrospective study was carried out to evaluate the notifications of adverse events related to vaccination during 2011-2017 in Mexico. During the follow-up period, 20,852,313 dose of pentavalent rotavirus vaccines were applied. Intestinal invagination was reported at a rate of 0.94 per 100,000 dose applied. The pentavalent rotavirus vaccine was shown in Mexico to be safe.
REFERENCES
Burke RM, Tate JE, Kirkwood CD, Duncan Steele A, Parashar UD. Current and new rotavirus vaccines. Review. Curr Opin Infect Dis. 2019; 32(5): 435-444.
World Health Organization. Rotavirus vaccines WHO position paper. Weekly Epidemiological Record. 2013; 88 (5): 49-64.
Cobertura vacunal. Datos y cifras. 16 de julio de 2018. Organización mundial de la Salud. [Consultado 01/07/2018] Disponible en: http://www.who.int/es/news-room/fact-sheets/detail/immunization-coverage.
Parashar UD, Glass RI. Public health. Progress toward rotavirus vaccines. Science. 2006; 312 (5775): 851-852.
Soares-Weiser K, Bergman H, Henschke N, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews. 2019; 3: CD008521.
Mortality GBD. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117-171.
Libster R, McNeal M, Walter EB, Shane AL, Winokur P, Crees G et al. VTEU Rotavirus Vaccine Study Work Group. Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics. 2016; 137 (2): e20152603.
Vesikari T, Matson DO, Dennehy P, Dennehy P, Van Damme P, Santosham M et al. Rotavirus efficacy and safety trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006; 354: 23-33.
Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006; 354: 11-22.
Vacuna contra rotavirus. [Consultado el 15 de agosto de 2019] Disponible en: http://www.dof.gob.mx/nota_detalle_popup.php?codigo=5387053.
Secretaría de Salud México. (2014). Programa de Acción Específico Vacunación Universal 2013-2018. Disponible en: [Consultado el 28 diciembre de 2018] http://www.censia.salud.gob.mx/contenidos/descargas/transparencia/especiales/PAE_Vacunacion_Universal_PAE_final_final.pdf.
Payne DC, Boom JA, Staat MA, Edwards KM, Szilagyi PG, Klein EJ. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children < 5 years of age, 2009-2011. Clin Infect Dis. 2013; 57: 13-20.
Programa de Vacunación Universal y Semanas Nacionales de Salud. Centro Nacional para la Salud de la Infancia y la Adolescencia. Secretaría de Salud. Lineamientos generales 2018. [Consultado el 2 de julio de 2018] Disponible en 4https://www.gob.mx/cms/uploads/attachment/file/294272/Lineamientos_PVU_y_SNS_2018_corregidos.pdf.
Manual De Vacunación 2017. Centro Nacional para la Salud de la Infancia y la Adolescencia. Secretaría de Salud. México. [Consultado 3/07/2018]. https://www.gob.mx/salud%7Ccensia/documentos/manual-de-vacunacion-edicion-2017.
Vacuna antirrotavirus. Secretaría de Salud. Disponible en: 1. https://www.gob.mx/salud/articulos/vacuna-antirrotavirus. Consultado el 18 de agosto de 2019.
Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics. 2013; 132: e25-33.
Manual de ESAVI 2018. Centro Nacional para la Salud de la Infancia y la Adolescencia. Secretaría de Salud. México 2018. [En prensa].
Reyna-Figueroa J, Vidal-Vázquez R, Richardson López-Collada V. Inmunización contra rotavirus en México con vacuna oral monovalente. Evaluación de los datos de dos años del sistema de reporte de eventos temporalmente asociados a vacunación. Rev Invest Clin. 2011; 63 (4): 391-339.
Castilla-Peóna M, Ramírez-Sandoval J, Reyes-Morales H, Reyes-López A. Diseño de estudios clínicos y causalidad: ¿la vacuna oral contra rotavirus causa invaginación intestinal? Boletín Médico del Hospital Infantil de México, 2015: 72(5): 346-352.
Inmunización, Vacunas y Productos Biológicos. Rotavirus. Organización mundial de la Salud. [Consultado el 1 de julio de 2018] Disponible en: http://www.who.int/immunization/diseases/rotavirus/es/.
Plosker GL. Pentavalent rotavirus vaccine (RotaTeq): A review of its use in the prevention of rotavirus gastroenteritis in Europe. Drugs. 2010; 70(9): 1165-1188.
Keating GM. Rotavirus vaccine (RotaTeq®). Paediatr Drugs. 2006; 8 (3): 197-202; discussion 203-4.
Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA et al. Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US Children, 2012-2013. Clin Infect Dis. 2015; 61 (12): 1792-1799.
Patel MM, López-Collada VR, Bulhões MM, de Oliveira LH, Bautista Márquez A, Flannery B et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011; 364: 2283-2292.
Rha B, Tate JE, Weintraub E, Haber P, Yen C, Patel M, Cortese MM et al. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines. 2014; 13: 1339-1348.